Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.

But maybe of more use are the hedges the company with $11 trillion in assets has articulated for a number of concerns that are currently weighing on investors' minds, according to strategists led by ...

Novo Nordisk shares climbed over 3% in Wednesday's pre-market trading as U.S. stock futures rebounded from a tech-driven ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular dis ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...